Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2020-07-31 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2020-07-31 English
Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refrac
Regulatory Filings Classification · 95% confidence The document is a corporate press release issued by Genmab A/S announcing positive topline results from a Phase 3 clinical trial (APOLLO study). It details the study's primary endpoints, the collaboration with Janssen, and the implications for regulatory submissions. This type of announcement regarding clinical trial results and product development updates is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement that does not fit into more specific categories like financial reports, proxy statements, or dividend notices.
2020-07-31 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is titled "Company Announcement" and dated July 31, 2020. It reports positive results from a Phase 3 clinical study (APOLLO) for a drug (daratumumab) and states that Janssen "intends to discuss the data with health authorities for potential regulatory submissions" and plans to "submit the data for presentation at an upcoming medical conference." This content is a press release announcing clinical trial results and future regulatory/presentation plans, which is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of material clinical data, it fits best under the Earnings Release category (ER), which often includes key operational and trial updates, even outside of standard quarterly reporting periods, or it could be classified as a general Regulatory Filing (RNS) if ER is strictly for financial performance. Given the focus on trial results and future submission plans, it is a significant corporate announcement. However, since it is not a formal financial report (like 10-K or IR) but an announcement of data that will lead to submissions, and it is not a transcript (CT) or a management discussion (MDA), the most appropriate category for a major, non-financial-statement-focused corporate update that isn't a specific transaction or governance change is often the general Regulatory Filing (RNS) or, if the results are considered the 'earnings' equivalent for a biotech, ER. Given the structure and content (key bullet points, detailed study info, contact info), it strongly resembles a press release announcing a major milestone, which often falls under ER or RNS. I will classify it as RNS as it is a general regulatory announcement about clinical progress, which is a common use case for RNS when ER is reserved for financial performance summaries. If the document were shorter and only announced the *publication* of this release, it would be RPA. Since this *is* the content, RNS is the safest general regulatory classification.
2020-07-31 English
6-K
Foreign Filer Report
2020-07-20 English
Major Shareholder Announcement
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled 'Major Shareholder Announcement' and references Section 30 of the Danish Capital Markets Act regarding a change in shareholding percentage (4.65%) by Société Générale S.A. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2020-07-20 English
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "Major Shareholder Announcement" and details that Société Générale S.A. holds a specific percentage (4.65%) of Genmab A/S's share capital and voting rights, referencing the Danish Capital Markets Act. This directly corresponds to the definition of a notification regarding changes in significant share ownership levels, which aligns with the 'Major Shareholding Notification' category (MRQ). Although it is a company announcement, the content is specific enough to warrant the MRQ code over the general RNS fallback.
2020-07-20 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.